**Age indications and schedule for MenB Vaccines**

- **MenB-FHbp** for persons aged 10 years & older
  - 3 dose series at 0, 2, 6 months
- **MenB-4C** for persons aged 10 years & older
  - 2 dose series at 0, ≥1 month after 1st dose

**Indications for Use**

**Routine Use**
Vaccinate persons aged 10 years and older who are at increased risk for meningococcal disease:
- Anatomic or functional asplenia, including sickle cell disease
- Persistent complement component deficiencies
  - Including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, factor D or taking eculizumab [Soliris®]
- Microbiologists routinely exposed to isolates of Neisseria meningitidis
- Exposure during a community outbreak attributable to serogroup B

**Consider use**
Based on provider clinical decision, persons aged 16 through 23 years without high risk conditions may receive either vaccine for short-term protection against most strains of serogroup B disease
- Preferred age is 16 through 18 years

**Vaccine Administration**
- Intramuscular (IM) injection in the deltoid of the arm
  - 1-1.5 inch, 22-25 gauge needle
- Use professional judgment in selecting needle length
- Can be given simultaneously with other vaccines, including MCV4
- The same MenB vaccine brand must be used for all doses to complete the series

**Storage and Handling**
- Store in the refrigerator
  - Between 35º-46ºF (2º-8ºC)
  - Do NOT freeze
- Keep in original box
  - Bexsero® and Trumenba™ supplied as 0.5 mL single-dose pre-filled syringe
- Shake prefilled syringes well before use
- Protect Bexsero® from light
- Lay Trumenba™ syringes flat on shelf
- Stand-alone purpose built units are preferred

**Contraindications**
- An anaphylactic (severe allergic) reaction to a prior dose or a component of MenB vaccines

**Precautions**
- Moderate to severe acute illness
- Bexsero® pre-filled syringes contain natural rubber latex in caps; may cause allergic reactions in latex sensitive individuals

**Further Points**
- Children less than age 10 years are not recommended to receive either vaccine, regardless of risk conditions
- Unlike Meningococcal Conjugate Vaccines (MCV4), MenB vaccines are not routinely recommended for adolescents aged 10 through 15 years without a risk condition, first-year college students living in residence halls, military recruits and international travelers
- There is no preference for the use of one brand of MenB vaccine over the other
- MenB vaccine should be deferred during pregnancy and should only be used if clearly needed
- Meningococcal Group B Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at [www.michigan.gov/immunize](http://www.michigan.gov/immunize) or your local health department
- Document Bexsero® as “MenB (Bexsero)” & Trumenba™ as “MenB (Trumenba)” in MCIR and on the vaccine administration record (VAR) & immunization record card,
- For information regarding meningococcal conjugate vaccine (MCV4) refer to the Meningococcal Conjugate Quick Looks at [www.michigan.gov/immunize](http://www.michigan.gov/immunize) under “Health Care Providers/Professionals.”

---

1 Advisory Committee on Immunization Practices (ACIP) designates vaccine recommendations as either category A or category B. Category A recommendations are made for all persons in an age or risk factor group. Category B recommendations are made for individual clinical decision making. Category A & B recommendations are covered under the Vaccines for Children (VFC) program and under the Affordable Care Act (ACA).

2 If different MenB products were administered for any of the doses, proceed with the next scheduled dose of the selected product with a minimum of 1 month since the last dose of either product, further information can be found at: [http://www.cdc.gov/vaccines/vis-vpd/vac-mening/faqs-hcp-adolescent-vaccine.html](http://www.cdc.gov/vaccines/vis-vpd/vac-mening/faqs-hcp-adolescent-vaccine.html)

Publicly purchased MenB can be administered to eligible children aged 10 years through 18 years with an indication for vaccination through the Vaccines for Children (VFC) Program in private providers’ offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information. Resource: “Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults”, 10/23/15 & “Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk”, 06/12/15, recommendations of the ACIP located at [www.cdc.gov/vaccines/recs](http://www.cdc.gov/vaccines/recs). Updates to this Quick Look handout will be posted at [www.michigan.gov/immunize](http://www.michigan.gov/immunize) under “Provider Information” January 6, 2016